Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeVitamin K for improved anticoagulation control in patients receiving warfarinVitamin K for improved anticoagulation control in patients receiving warfarinWarfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleedingManagement of antithrombotic therapy during cardiac implantable device surgeryClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenetics and anaesthesia: the value of genetic profilingStroke genetics: prospects for personalized medicineSpotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatranVKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapyEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinComparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort StudyWarfarin genotyping with hybridization-induced aggregation on a poly(ethylene terephthalate) microdevice.Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries.Best strategies for patient education about anticoagulation with warfarin: a systematic reviewNew pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting.Estimation of the warfarin dose with clinical and pharmacogenetic data.10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Integration of genetic, clinical, and INR data to refine warfarin dosing.National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiariesEthnicity-specific pharmacogenetics: the case of warfarin in African AmericansFibrate/Statin initiation in warfarin users and gastrointestinal bleeding riskTesting of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment).Characteristics of ambulatory anticoagulant adverse drug events: a descriptive studyIndividualized medical decision making: necessary, achievable, but not yet attainable.Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study).Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert systemPrescribing warfarin appropriately to meet patient safety goals.Analysis of gene-gene interactions using gene-trait similarity regression.Computed Tomography Angiography in Patients Evaluated for Acute Pulmonary Embolism with Low Serum D-dimer Levels: A Prospective StudyGenotype-based dosing algorithms for warfarin therapy: data review and recommendations.Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement InitiativeA Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.Traumatic intracranial hemorrhage correlates with preinjury brain atrophy, but not with antithrombotic agent use: a retrospective study.Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.Emerging clinical applications in cardiovascular pharmacogenomics.Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy
P2860
Q24185813-EDC9B1CE-A5D8-4549-BAC5-070A9DD6E363Q24194649-54D4E22A-186F-4F52-8855-FCA07AC1F052Q24202915-74D9AF9D-4EF5-449D-95D1-2ADA02947D02Q24647605-2C30A3CF-3D88-4C2D-8C38-E2120F836CCCQ26746160-BD51D202-D91F-419C-86A1-71CA8C4823C0Q26823542-ABACAE8A-A652-4A2E-B7C4-4A59941D5B41Q26859221-E744F386-9B7D-49B5-9467-215F318AF0E1Q27006885-5271BD95-F0C9-4593-B944-66F778A49164Q28066262-D7184C69-6284-4D73-BE2F-0B15B7D04539Q28114887-2AB011EB-EAEC-4CDD-A6E6-5B079DFD7B5BQ28276514-2C5A8AD5-478F-460F-9421-FC84F5F3A344Q28552407-B9EE4AA2-049A-4D05-A496-E0C1BC26855CQ30275196-F6F8581B-3665-4887-884A-9A8103831540Q30356138-5CC5ADB8-31B2-4807-8184-1C1DECEA9ACCQ33319899-218E9273-B410-4359-A58F-643DA3601225Q33364524-6E740CA7-E6D8-47D4-B68F-502B96B441D4Q33410725-3F87147B-1D6F-43EE-9B7A-7DDACD4A22F0Q33517162-29D3D229-EF40-466D-80EA-5877CD6DA218Q33550741-94744102-ADE6-4A1D-BC77-7C9FDA040415Q33553982-9C58A638-D2CA-443D-8A12-CB18DA566CAAQ33591111-EF10DBBB-A6CC-4FAD-8D41-A4AD4E149983Q33617751-0EC09E75-EB32-4DAB-9905-F5F8576B8ED0Q33704981-DEEDCEC8-A647-4C52-A881-CCB97B3E2136Q33745957-47510A6C-C20A-4B60-8FF8-46F260D835ECQ33752536-C9EACC32-AC63-4BD3-BAA4-AFC79B8C570FQ33753659-B5BEA199-E889-43CC-B638-384B3BFA27E7Q33770184-BA504AC9-454D-488E-AB5A-328E111FE654Q33792352-FBF10DC0-C993-4C71-885D-B4A4F762F642Q33912263-77388049-0FA5-4085-A51D-C77414A60C66Q33932089-4D7B42EA-EA8D-461D-BCBA-230B60F89989Q33970683-E4C5FC95-7B4E-4F24-A978-93494D7C8448Q34027320-CEC916A3-3ED7-46CB-87F7-6E31BC63EDAAQ34065133-407F6D52-EB44-41AF-A9EF-24C5BC8A1C5FQ34096562-D07FEC3E-EAFB-43F8-88D5-8640AA496695Q34177159-D5ED55D5-5D87-41B3-AC84-2F49E68551F3Q34273608-ED01D13E-9261-46F2-BF20-BCDAF9079CDFQ34287404-FF325FE3-CD5D-420D-A328-0AA29397A856Q34364050-A99F23DF-3F96-4CE0-9060-37DE8F57222CQ34400491-896EC10A-8E49-4096-890B-2F9D7047C593Q34401539-872E90EA-78BD-4199-ADEC-D62B9814E7DB
P2860
Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Bleeding complications with wa ...... esulting in regulatory action.
@ast
Bleeding complications with wa ...... esulting in regulatory action.
@en
Bleeding complications with wa ...... esulting in regulatory action.
@nl
type
label
Bleeding complications with wa ...... esulting in regulatory action.
@ast
Bleeding complications with wa ...... esulting in regulatory action.
@en
Bleeding complications with wa ...... esulting in regulatory action.
@nl
prefLabel
Bleeding complications with wa ...... esulting in regulatory action.
@ast
Bleeding complications with wa ...... esulting in regulatory action.
@en
Bleeding complications with wa ...... esulting in regulatory action.
@nl
P2093
P1476
Bleeding complications with wa ...... esulting in regulatory action.
@en
P2093
Diane K Wysowski
Lynette Swartz
Parivash Nourjah
P304
P356
10.1001/ARCHINTE.167.13.1414
P407
P577
2007-07-01T00:00:00Z